Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2019-01-11
2025-12-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Predictive and Prognostic Markers in Patients With Non-small Cell Lung Cancer
NCT00958555
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer
NCT01414595
Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype
NCT01774526
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
NCT02214134
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
NCT01580982
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 21 years
* WHO performance status ≤ 2
* Life expectancy of ≥ 12 weeks
* Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):
* Adequate bone marrow function as shown by: ANC ≥ 1.0 x 10\^9/L, Platelets ≥ 75 x 10\^9/L, Hb ≥ 7.5 g/dL
* Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or ≤3.0 x ULN if liver metastases are present)
* Willing to provide signed informed consent
* Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis with the study team, for potential enrolment
Exclusion Criteria
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Singapore General Hospital
OTHER
National Cancer Centre, Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Tan, BSc, MBBS, MRCP
Role: PRINCIPAL_INVESTIGATOR
National Cancer Centre, Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Brunei Cancer Centre
Brunei, , Brunei
Hong Kong Integrated Oncology Centre
Hong Kong, , Hong Kong
The Chinese University of Hong Kong, Department of Clinical Oncology
Hong Kong, , Hong Kong
Rajiv Ghandhi Cancer Institute and Research Centre
New Delhi, , India
Penang Adventist Hospital
George Town, , Malaysia
Pantai Hospital, Kuala Lumpur
Kuala Lumpur, , Malaysia
University Malaya Medical Centre, Clinical Oncology Department
Kuala Lumpur, , Malaysia
Beacon Hospital
Petaling Jaya, , Malaysia
National Cancer Centre Singapore
Singapore, , Singapore
Phramongkutklao Hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATORG001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.